Clinical trial of cellular immunotherapy for malignant tumor (alpha-beta T cell-based cancer immunotherapy) - Alpha-beta T cell-based cancer immunotherapy

Start Date12 Nov 2012

Sponsor / Collaborator-

100 Clinical Results associated with Alpha-Beta T Cells(Editas)

100 Translational Medicine associated with Alpha-Beta T Cells(Editas)

100 Patents (Medical) associated with Alpha-Beta T Cells(Editas)

Literatures (Medical) associated with Alpha-Beta T Cells(Editas)

01 Nov 2024·European Journal of Immunology

The potential of γδ CAR and TRuC T cells: An unearthed treasure

Review

Author: Zintchenko, Marina ; Nguyen, Trang ; Minguet, Susana ; Schamel, Wolfgang W. ; Fehse, Boris ; Briquez, Priscilla S.

AbstractRecent years have witnessed the success of αβ T cells engineered to express chimeric antigen receptors (CARs) in treating haematological cancers. CARs combine the tumour antigen binding capability of antibodies with the signalling functions of the T‐cell receptor (TCR) ζ chain and co‐stimulatory receptors. Despite the success, αβ CAR T cells face limitations. Possible solutions would be the use of γδ T cells and new chimeric receptors, such as TCR fusion constructs (TRuCs). Notably, γδ CAR T cells are gaining traction in pre‐clinical and clinical studies, demonstrating a promising safety profile in several pilot studies. This review delves into the current understanding of γδ CAR and TCR fusion construct T cells, exploring the opportunities and challenges they present for cancer treatment.

27 May 2013·TransplantationQ2 · MEDICINE

Effectiveness of Topical Immunosuppressants in Prevention and Treatment of Rejection in Face Allotransplantation

Q2 · MEDICINE

Article

Author: Antonio Rampazzo ; Maria Zofia Siemionow ; Selman Hakki Altuntas ; Bahar Bassiri Gharb ; Jason Stratton ; Joanna Cwykiel ; Maria Madajka

BACKGROUNDThe use of topical immunosuppressants has been anecdotally reported for the treatment of rejection in vascularized composite allotransplantation. The aim of this study was to evaluate the effectiveness of topical tacrolimus and clobetasol in the prevention and treatment of rejection.METHODSSeventy-six hemiface allotransplants, between ACI (RT1) donors and Lewis (RT1) recipients, were performed in 11 groups and treated with topical tacrolimus or clobetasol, or in combination with systemic cyclosporine A and anti-αβ-T-cell receptor antibody for 1 week. Topical treatment increased the survival of the allograft in all groups.RESULTSBest outcomes were obtained in the groups treated with systemic therapy and topical tacrolimus. Expression of proinflammatory cytokines interleukin 2, interferon γ, tumor necrosis factor α, and transforming growth factor β correlated with clinical signs of rejection and the final outcomes. Clobetasol application was associated with a marked depletion of lymphocytic populations, and dermal and epidermal atrophy.CONCLUSIONSBoth topical tacrolimus and clobetasol were effective in treating episodes of acute rejection, and the best outcomes were achieved when their application was initiated after systemic immunosuppression. Topical tacrolimus proved to be a preferable adjunct agent to the systemic therapy by preventing both the local and systemic complications.

01 Jun 2010·Behavioural Brain ResearchQ3 · PSYCHOLOGY

α-Tocopherol administration produces an antidepressant-like effect in predictive animal models of depression

Q3 · PSYCHOLOGY

Article

Author: Luiz Felipe de Souza ; Andiara E. Freitas ; Caroline Brocardo ; Kelly R. Lobato ; Alcir L. Dafré ; Josiane Budni ; Ricardo W. Binfaré ; Ana Lúcia S. Rodrigues ; Cristiane L.R. Wagner ; Samira Flesch ; Chandra C. Cardoso ; Patrícia S. Brocardo

This study investigated the antidepressant potential of alpha-tocopherol, the most active and abundant form of vitamin E, in the forced swim test (FST) and tail suspension test (TST). The acute oral treatment with alpha-tocopherol at the doses of 30 and 100mg/kg reduced the immobility time in the FST and in the TST. A single i.c.v. administration of alpha-tocopheryl phosphate, a water-soluble analogue of alpha-tocopherol, also reduced the immobility time in the FST (0.1 and 1 nmol/site) and in the TST (0.1 nmol/site). In addition, the long-term treatment (28 days) with alpha-tocopherol (10mg/kg, p.o.) significantly reduced the immobility time in the FST. Moreover, a subeffective dose of alpha-T (10mg/kg, p.o.) potentiated the effect of fluoxetine (10mg/kg, p.o.) in the FST. The long-term treatment with alpha-T was able to increase the glutathione (GSH) antioxidant defense system, while the acute treatment was not. The long-term treatment with alpha-tocopherol (10mg/kg) increased the GSH levels in the hippocampus and in the prefrontal cortex and increased the glutathione peroxidase and glutathione reductase activity in the hippocampus (10mg/kg) and in the prefrontal cortex (10-100mg/kg). The long-term treatment with fluoxetine (10mg/kg, p.o.), a positive control, was also able to increase the GSH levels in the hippocampus, but failed to alter the activity of both enzymes. Besides the specific antidepressant-like effect, long-term, but not the acute treatment with alpha-T, especially in the doses that produced an antidepressant-like effect (10mg/kg), improved the antioxidant defenses in the mouse hippocampus and prefrontal cortex, two structures closely implicated in the pathophysiology of depression.

100 Deals associated with Alpha-Beta T Cells(Editas)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neoplasms	IND Application	US	Editas Medicine, Inc.	17 Jun 2024
Neoplasms	IND Application	US	Bristol Myers Squibb Co.	17 Jun 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Alpha-Beta T Cells(Editas)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation